Rocket Lab stock is volatile, but that kind of comes with the territory when investing in unprofitable start-up stocks that are hard to value on the earnings-that-they-don't-have-yet.

Rocket Lab stock is volatile, but that kind of comes with the territory when investing in unprofitable start-up stocks that are hard to value on the earnings-that-they-don't-have-yet.

Rocket Lab will acquire the company for $275 million, which includes a mix of $125 million of cash and $150 million in privately placed shares of Rocket Lab common stock.

Eli Lilly saw its shares jump by 15% on Thursday after unveiling positive results from a clinical trial of its experimental oral drug.

Chime’s stock soars in its debut, to extend the streak of IPOs that have witnessed strong investor demand.

The pharmaceutical giant dished out an up-front payment of $1.25 billion, with potential clinical and regulatory milestones of up to $4.8 billion for 3SBio, not including royalties.

Editas Medicine, Inc. (NASDAQ:EDIT) is a clinical-stage biotech company focused on developing gene-editing therapies using CRISPR technology to treat genetic disorders by modifying patients ...

High-definition pictures of a World War I-era U.S. Navy submarine that sank to the bottom of the ocean near San Diego were just released, over a century after it was lost at sea.

The Justice Department is making a push to disrupt the schemes, which use social media to find buyers for risky stocks.